spacer
home > ebr > summer 2018 > understanding biosimilars
PUBLICATIONS
European Biopharmaceutical Review

Understanding Biosimilars

The development and production of any protein biologic relies on sound and robust structural data to demonstrate that the correct molecule has been produced. The data should allow an assessment of all relevant attributes of the molecule, and, from these data, in conjunction with bioassay information, conclusions can be drawn regarding structure and function. This is particularly true for biosimilars where analytical data is the foundation of any biosimilarity claim.

In a structural sense, the most common question that needs to be answered is “Is the amino acid sequence of my molecule correct?” This is true of novel biologics, where recombinant forms of a natural product are being produced, and is also critical for biosimilar production, where it is essential that the amino acid sequence of the biosimilar is shown to be the same as that of the innovator. Whatever the product, if the sequence is not as expected or comparable with an innovator, then the production process must be corrected before further development can be considered.

With the rise of modern analytical technologies such as mass spectrometry and its ability to generate significant structural information from proteins, sequence determination at the protein level has become more feasible. Sequence analysis at this stage (rather than DNA level) is able to confirm that correct translation has taken place and demonstrate that no issue has arisen with codon usage. Indeed, regulatory authorities are now expecting that amino acid sequence information is generated to provide confirmation of the comparability of biosimilar/innovator protein sequences, rather than relying on the DNA sequences alone. For example, the EMA Biosimilar Guideline states, “The target amino acid sequence of the biosimilar should be confirmed and is expected to be the same as for the reference medicinal product.” The comparable US FDA biosimilar guideline states, “It is expected that the expression construct for a proposed product will encode the same primary amino acid sequence as its reference product.” (1-2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Richard Easton obtained his PhD in glycoprotein structural characterisation using MS from Imperial College of Science, Technology and Medicine, UK. He subsequently spent several years there as a postdoctoral research scientist working in the field of glycoprotein structural characterisation with emphasis on glycan elucidation. He moved to GlaxoSmithKline for a short time where he was head of MS for the toxicoproteomics and safety assessment group. Richard joined M-Scan (now part of SGS Life Sciences) as a biochemist and became the Team Leader for Carbohydrate Analysis before being appointed Principal Scientist. He joined BioPharmaSpec in 2016 as Technical Director for Structural Analysis and is responsible for management of all aspects of carbohydrate and glycoprotein characterisation at the primary structure level.

Dr Andrew Reason is the founder, CEO, and Managing Director at BioPharmaSpec. He has 25 years of experience in analysis of both novel and biosimilar biopharmaceuticals and has been involved in the commercialisation of a number of analytical methods for characterising proteins. In addition to his scientific and managerial duties, Andrew has contributed to many industry publications and is a regular presenter at conferences. Andrew is also currently a Visiting Professor at the University of Warwick.
spacer
Dr Richard Easton
spacer
spacer
spacer
Dr Andrew Reason
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Realising the potential of single-use technology – As published in Manufacturing Chemist

In this article Zenith Technologies’ Global Director of Managed Services David Staunton and Scott Ripley, Global Marketing Director at GE Healthcare, discuss the benefits and patient impact of single-use technology with Manufacturing Chemist.
More info >>

White Papers

Successfully managing the unique demands of cell therapy supply chains

PCI Pharma Services

Cell therapy professionals joined a specialist webinar by industry experts from PCI Clinical Services and TrakCel, addressing the unique complexity of an autologous therapy supply chain. Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, Associate Director, Technical Services, PCI Clinincal Services, and Dr. Matthew Lakelin, Vice President, Scientific Affairs and Business Development, TrakCel . Here, we present the white paper from that webinar event.
More info >>

 
Industry Events

Bio Europe Spring 2019

25-27 March 2019, Messe Wien Exhibition and Congress Center, Vienna

BIO-Europe Spring® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative startups.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement